Skip to content

Nasdaq · CIK 0001984086

SEPN Septerna, Inc.

Insider trading from SEC Form 4. Last filing 32 d ago. Close $38.37 on Oct 9, 2026, +112% from the 52-week low and -20% from the high.

Last 90 days

Net insider value
-$126k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$126k by 1 insider
Insiders on file
8
with a Form 4 at this company

Price and insider trades, last year

SEPNOct 9, 2026 · close 38.37

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Septerna, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
0WeakDaniel D. Long
SVP, Drug Discovery
sell
$126k
3,333 shares
-3%-
40ModerateAlan Ezekowitz
director
buy
$92k
13,319 shares
+13%-
51ModerateAlan Ezekowitz
director
buy
$516k
86,681 shares
+498%-
43ModerateJeffrey Finer
CEO and President
buy
$97k
17,000 shares
+2%-
58ModerateRa Capital Management, L.p.
director, owner
buy
$75M
4,170,000 shares
+246%-
43ModerateThird Rock Ventures V, L.P.
owner
buy
$12M
650,000 shares
+11%-

Transactions

The last 31 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 8, 2026Rajiv Patni
Chief Medical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+275,000$0.00$0275,00032 d ago
Sep 1, 2026Daniel D. Long
SVP, Drug Discovery
MOption exercise
Common Stock10b5-1
+3,333$2.76$9,19999,74539 d ago
Sep 1, 2026Daniel D. Long
SVP, Drug Discovery
SOpen-market sale
Common Stock10b5-1
-3,333$37.83$126k96,41239 d ago
Sep 1, 2026Daniel D. Long
SVP, Drug Discovery
MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-3,333$0.00$09,08539 d ago
Jun 17, 2025Abraham Bassan
director
AGrant or award
Stock Option (Right to Buy)derivative
+16,623$0.00$016,623Jun 20, 2025
Jun 17, 2025Bernard Coulie
director
AGrant or award
Stock Option (Right to Buy)derivative
+16,623$0.00$016,623Jun 20, 2025
Jun 17, 2025Alan Ezekowitz
director
AGrant or award
Stock Option (Right to Buy)derivative
+16,623$0.00$016,623Jun 20, 2025
Jun 17, 2025Ra Capital Management, L.p.
director, owner
AGrant or award
Stock Option (Right to Buy)derivativeindirect: See Footnotes
+16,623$0.00$016,623Jun 20, 2025
Apr 2, 2025Jeffrey Finer
CEO and President
MOption exercise
Common Stock
+50,000$2.76$138k821,907Apr 4, 2025
Apr 3, 2025Jeffrey Finer
CEO and President
MOption exercise
Common Stock
+5,000$2.76$14k826,907Apr 4, 2025
Apr 2, 2025Jeffrey Finer
CEO and President
MOption exercise
Stock Option (Right to Buy)derivative
-50,000$0.00$0402,212Apr 4, 2025
Apr 3, 2025Jeffrey Finer
CEO and President
MOption exercise
Stock Option (Right to Buy)derivative
-5,000$0.00$0397,212Apr 4, 2025
Mar 7, 2025Alan Ezekowitz
director
POpen-market purchase
Common Stock
+13,319$6.93$92k117,420Mar 10, 2025
Mar 4, 2025Alan Ezekowitz
director
POpen-market purchase
Common Stock
+7,491$6.35$48k24,911Mar 6, 2025
Mar 5, 2025Alan Ezekowitz
director
POpen-market purchase
Common Stock
+37,835$5.82$220k62,746Mar 6, 2025
Mar 6, 2025Alan Ezekowitz
director
POpen-market purchase
Common Stock
+41,355$6.00$248k104,101Mar 6, 2025
Feb 25, 2025Jeffrey Finer
CEO and President
POpen-market purchase
Common Stock
+10,000$5.68$57k764,907Feb 27, 2025
Feb 26, 2025Jeffrey Finer
CEO and President
POpen-market purchase
Common Stock
+4,000$5.70$23k768,907Feb 27, 2025
Feb 27, 2025Jeffrey Finer
CEO and President
POpen-market purchase
Common Stock
+3,000$5.80$17k771,907Feb 27, 2025
Oct 28, 2024Ra Capital Management, L.p.
director, owner
CConversion
Common Stockindirect: See footnotes
+1,695,515--1,695,515Oct 30, 2024
Oct 28, 2024Ra Capital Management, L.p.
director, owner
CConversion
Common Stockindirect: See footnotes
+1,130,343--1,130,343Oct 30, 2024
Oct 28, 2024Ra Capital Management, L.p.
director, owner
POpen-market purchase
Common Stockindirect: See footnotes
+3,828,400$18.00$69M5,523,915Oct 30, 2024
Oct 28, 2024Ra Capital Management, L.p.
director, owner
POpen-market purchase
Common Stockindirect: See footnotes
+341,600$18.00$6.1M1,471,943Oct 30, 2024
Oct 28, 2024Ra Capital Management, L.p.
director, owner
CConversion
Series B Preferred Stockderivativeindirect: See Footnotes
-14,598,896--0Oct 30, 2024
Oct 28, 2024Ra Capital Management, L.p.
director, owner
CConversion
Series B Preferred Stockderivativeindirect: See Footnotes
-9,732,596--0Oct 30, 2024
Oct 28, 2024Third Rock Ventures V, L.P.
owner
CConversion
Common Stock
+4,790,773$0.00$05,845,091Oct 28, 2024
Oct 28, 2024Third Rock Ventures V, L.P.
owner
CConversion
Common Stockindirect: See Footnotes
+2,872,956$0.00$02,872,956Oct 28, 2024
Oct 28, 2024Third Rock Ventures V, L.P.
owner
POpen-market purchase
Common Stock
+370,500$18.00$6.7M6,215,591Oct 28, 2024
Oct 28, 2024Third Rock Ventures V, L.P.
owner
POpen-market purchase
Common Stockindirect: See Footnotes
+279,500$18.00$5.0M3,152,456Oct 28, 2024
Oct 28, 2024Third Rock Ventures V, L.P.
owner
CConversion
Series A Preferred Stockderivative
-41,250,000$0.00$00Oct 28, 2024
Oct 28, 2024Third Rock Ventures V, L.P.
owner
CConversion
Series B Preferred Stockderivativeindirect: See Footnotes
-24,737,017$0.00$00Oct 28, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

SEPN insider trading: Septerna, Inc. | InsiderTell